Market Tracker

06/27 5:19am ET

Immunomedics Inc (NASDAQ:IMMU)

2.17
Delayed Data
As of Jun 24
 -0.33 / -13.20%
Today’s Change
1.50
Today|||52-Week Range
5.44
-29.32%
Year-to-Date
Cancer doctors face next drug challenge
Jun 01 / FT.com - Paid Partner Content
 

Today’s Trading

Previous close2.50
Today’s open2.36
Day’s range2.10 - 2.46
Volume13,369,548
Average volume (3 months)1,804,446
Market cap$205.7M
Dividend yield--
Data as of 06/24/2016

Growth & Valuation

Earnings growth (last year)-21.43%
Earnings growth (this year)-8.82%
Earnings growth (next 5 years)+20.00%
Revenue growth (last year)-37.48%
P/E ratioNM
Price/Sales67.02
Price/Book--

Competitors

 Today’s
change
Today’s
% change
AXGNAxoGen Inc-0.10-1.58%
IRIXIRIDEX Corp-0.28-1.89%
CUTRCutera Inc+0.23+2.12%
FONRFonar Corp-0.53-2.43%
Data as of 06/24/2016

Financials

Next reporting dateAugust 18, 2016
EPS forecast (this quarter)-$0.11
Annual revenue (last year)$5.7M
Annual profit (last year)-$48.0M
Net profit margin-849.13%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, Chief Scientific &
Patent Officer
David M. Goldenberg
President, Chief Executive Officer &
Director
Cynthia L. Sullivan
Corporate headquarters
Morris Plains, New Jersey

Forecasts